Wall Street brokerages expect that BRAINSWAY LTD/S (NASDAQ:BWAY) will announce sales of $6.25 million for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for BRAINSWAY LTD/S’s earnings. The lowest sales estimate is $6.20 million and the highest is $6.30 million. The company is scheduled to announce its next quarterly earnings report on Monday, January 1st.
On average, analysts expect that BRAINSWAY LTD/S will report full year sales of $23.05 million for the current financial year, with estimates ranging from $23.00 million to $23.10 million. For the next year, analysts forecast that the business will post sales of $30.30 million, with estimates ranging from $29.50 million to $31.10 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow BRAINSWAY LTD/S.
BRAINSWAY LTD/S (NASDAQ:BWAY) last announced its quarterly earnings results on Monday, November 25th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.01. The business had revenue of $5.93 million during the quarter, compared to the consensus estimate of $5.75 million.
BWAY traded up $0.03 during trading hours on Friday, hitting $11.55. The company’s stock had a trading volume of 2,580 shares, compared to its average volume of 11,544. The business’s 50-day moving average price is $11.55 and its 200-day moving average price is $10.08. BRAINSWAY LTD/S has a 12 month low of $8.00 and a 12 month high of $12.53.
A hedge fund recently raised its stake in BRAINSWAY LTD/S stock. Raymond James & Associates lifted its stake in BRAINSWAY LTD/S (NASDAQ:BWAY) by 54.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 28,500 shares of the company’s stock after purchasing an additional 10,000 shares during the period. Raymond James & Associates owned about 0.26% of BRAINSWAY LTD/S worth $278,000 at the end of the most recent quarter. 12.48% of the stock is owned by institutional investors and hedge funds.
About BRAINSWAY LTD/S
Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation systems for treating various conditions, including autism, Alzheimer's disease, bipolar disorders, chronic pains, depressive disorders, Parkinson's diseases, schizophrenia, smoking cessation, post-traumatic stress disorders, multiple sclerosis, obsessive compulsive disorders, and stroke rehabilitation.
Featured Article: Understanding debt-to-equity ratio in fundamental analysis
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BRAINSWAY LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BRAINSWAY LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.